APPLIED THERAPEUTICS INC (APLT) Stock Fundamental Analysis

NASDAQ:APLT • US03828A1016

0.103 USD
+0 (+0.19%)
At close: Feb 2, 2026
0.1051 USD
+0 (+2.04%)
After Hours: 2/2/2026, 8:00:00 PM
Fundamental Rating

1

Taking everything into account, APLT scores 1 out of 10 in our fundamental rating. APLT was compared to 521 industry peers in the Biotechnology industry. APLT may be in some trouble as it scores bad on both profitability and health. APLT is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year APLT has reported negative net income.
  • APLT had a negative operating cash flow in the past year.
  • APLT had negative earnings in each of the past 5 years.
  • APLT had a negative operating cash flow in each of the past 5 years.
APLT Yearly Net Income VS EBIT VS OCF VS FCFAPLT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -52.77%, APLT is in line with its industry, outperforming 47.42% of the companies in the same industry.
Industry RankSector Rank
ROA -52.77%
ROE N/A
ROIC N/A
ROA(3y)-185.04%
ROA(5y)-152.5%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
APLT Yearly ROA, ROE, ROICAPLT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500 -1K -1.5K -2K

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for APLT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
APLT Yearly Profit, Operating, Gross MarginsAPLT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 -5K -10K -15K -20K

0

2. Health

2.1 Basic Checks

  • APLT does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, APLT has more shares outstanding
  • APLT has more shares outstanding than it did 5 years ago.
  • APLT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
APLT Yearly Shares OutstandingAPLT Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
APLT Yearly Total Debt VS Total AssetsAPLT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

  • APLT has an Altman-Z score of -35.12. This is a bad value and indicates that APLT is not financially healthy and even has some risk of bankruptcy.
  • The Altman-Z score of APLT (-35.12) is worse than 89.29% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -35.12
ROIC/WACCN/A
WACC12.25%
APLT Yearly LT Debt VS Equity VS FCFAPLT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M

2.3 Liquidity

  • APLT has a Current Ratio of 0.96. This is a bad value and indicates that APLT is not financially healthy enough and could expect problems in meeting its short term obligations.
  • APLT has a worse Current ratio (0.96) than 86.23% of its industry peers.
  • A Quick Ratio of 0.96 indicates that APLT may have some problems paying its short term obligations.
  • APLT has a worse Quick ratio (0.96) than 85.28% of its industry peers.
Industry RankSector Rank
Current Ratio 0.96
Quick Ratio 0.96
APLT Yearly Current Assets VS Current LiabilitesAPLT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

3

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 93.20% over the past year.
  • Looking at the last year, APLT shows a very negative growth in Revenue. The Revenue has decreased by -90.43% in the last year.
EPS 1Y (TTM)93.2%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%72.92%
Revenue 1Y (TTM)-90.43%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%719.67%

3.2 Future

  • The Earnings Per Share is expected to grow by 13.83% on average over the next years. This is quite good.
  • Based on estimates for the next years, APLT will show a very strong growth in Revenue. The Revenue will grow by 206.95% on average per year.
EPS Next Y32.11%
EPS Next 2Y20.62%
EPS Next 3Y19.8%
EPS Next 5Y13.83%
Revenue Next Year80.83%
Revenue Next 2Y50.35%
Revenue Next 3Y364.93%
Revenue Next 5Y206.95%

3.3 Evolution

APLT Yearly Revenue VS EstimatesAPLT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M
APLT Yearly EPS VS EstimatesAPLT Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 -1 -2 -3 -4

0

4. Valuation

4.1 Price/Earnings Ratio

  • APLT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year APLT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
APLT Price Earnings VS Forward Price EarningsAPLT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
APLT Per share dataAPLT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6

4.3 Compensation for Growth

  • APLT's earnings are expected to grow with 19.80% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y20.62%
EPS Next 3Y19.8%

0

5. Dividend

5.1 Amount

  • No dividends for APLT!.
Industry RankSector Rank
Dividend Yield 0%

APPLIED THERAPEUTICS INC

NASDAQ:APLT (2/2/2026, 8:00:00 PM)

After market: 0.1051 +0 (+2.04%)

0.103

+0 (+0.19%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-13
Earnings (Next)04-13
Inst Owners60.63%
Inst Owner Change-43.35%
Ins Owners2.01%
Ins Owner Change-75.76%
Market Cap14.86M
Revenue(TTM)1.00M
Net Income(TTM)-18.14M
Analysts48.89
Price Target0.26 (152.43%)
Short Float %1.07%
Short Ratio0.14
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)9.92%
Min EPS beat(2)8.96%
Max EPS beat(2)10.87%
EPS beat(4)4
Avg EPS beat(4)81.18%
Min EPS beat(4)8.96%
Max EPS beat(4)282.27%
EPS beat(8)5
Avg EPS beat(8)-14.9%
EPS beat(12)7
Avg EPS beat(12)-10.44%
EPS beat(16)10
Avg EPS beat(16)-5.79%
Revenue beat(2)1
Avg Revenue beat(2)47.06%
Min Revenue beat(2)-100%
Max Revenue beat(2)194.12%
Revenue beat(4)1
Avg Revenue beat(4)-26.47%
Min Revenue beat(4)-100%
Max Revenue beat(4)194.12%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)-91.3%
EPS NQ rev (1m)0%
EPS NQ rev (3m)19.3%
EPS NY rev (1m)0%
EPS NY rev (3m)6.99%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)200%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 14.86
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.1
EYN/A
EPS(NY)-0.44
Fwd EYN/A
FCF(TTM)-0.6
FCFYN/A
OCF(TTM)-0.6
OCFYN/A
SpS0.01
BVpS0
TBVpS0
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -52.77%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-185.04%
ROA(5y)-152.5%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.96
Quick Ratio 0.96
Altman-Z -35.12
F-Score3
WACC12.25%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)93.2%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%72.92%
EPS Next Y32.11%
EPS Next 2Y20.62%
EPS Next 3Y19.8%
EPS Next 5Y13.83%
Revenue 1Y (TTM)-90.43%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%719.67%
Revenue Next Year80.83%
Revenue Next 2Y50.35%
Revenue Next 3Y364.93%
Revenue Next 5Y206.95%
EBIT growth 1Y27.45%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year2.81%
EBIT Next 3Y26.24%
EBIT Next 5YN/A
FCF growth 1Y-60.35%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-60.35%
OCF growth 3YN/A
OCF growth 5YN/A

APPLIED THERAPEUTICS INC / APLT FAQ

Can you provide the ChartMill fundamental rating for APPLIED THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 1 / 10 to APLT.


What is the valuation status for APLT stock?

ChartMill assigns a valuation rating of 0 / 10 to APPLIED THERAPEUTICS INC (APLT). This can be considered as Overvalued.


How profitable is APPLIED THERAPEUTICS INC (APLT) stock?

APPLIED THERAPEUTICS INC (APLT) has a profitability rating of 0 / 10.


How financially healthy is APPLIED THERAPEUTICS INC?

The financial health rating of APPLIED THERAPEUTICS INC (APLT) is 0 / 10.